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e-mail address: etu@uic.eduElmer Y. Tu, MD ⇑AbstractMedical treatment of ophthalmic diseases relies primarily on the use of multidose drugs. Short term use is highly effective usually
with little local toxicity. However, chronic use of these preparations not only increases the likelihood of microbial contamination
and secondary ocular infection, but also of toxicity from the drug formulation itself. Increasing awareness of the toxicity of oph-
thalmic preservatives has led to an increasing variety of preservative schemes ranging from ‘‘self-preservation’’ to ionic buffer sys-
tems. Beyond outdated testing methods, the anti-microbial efficacy of most of these systems is poorly defined, potentially placing
these preparations at an unknown risk of contamination by unmonitored, untested organisms. No uniformity in toxicity testing
exists which further complicates the clinician’s judgment of the risk–benefit of using a particular drug formulation. In this manu-
script we examine in detail each of the current employed ophthalmic preservative regimens with respect to their known antimi-
crobial activity and potential toxicity, where known. We also survey the most popular ophthalmic preparations, detailing their
preservation schemes as well as concentrations to help the clinician in choosing an appropriate formulation for the treatment
of various ophthalmic diseases.
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Topical ophthalmic medications are the mainstay of ther-
apy for almost all ocular disorders of the anterior segment
including dry eye, glaucoma, ocular surface infections and
tumors. Topical dosing provides direct access to higher con-
centrations of a drug at its therapeutic target while minimiz-
ing or avoiding systemic side effects which might otherwise
limit their use. Several medications deemed too toxic for sys-
temic use can be used safely on the eye, e.g. neomycin. Short
term use of commercially available topical ophthalmic prepa-
rations in an otherwise healthy eye is very safe and is associ-
ated with few local complications. However, many drugs
require extended or chronic, repeated applications for con-trol or maintenance of disease. In this instance, side effects
or toxicity from the active drug can increase in frequency.
For example, with extended use, prostaglandin analogs
may cause complications ranging from simple hyperemia or
cosmetically troublesome pigmentation to severe prosta-
glandin associated periorbitopathy.1,2
Long term, repeated dosing of topical medications pre-
sents several other challenges that are common to all medi-
cations. Cost and compliance for chronic use often
necessitates the use of multidose preparations. Although
the healthy ocular surface is relatively resistant to microbial
challenge, direct applications of a high load of microorgan-
isms may overwhelm the normal protective mechanisms lead-
ing to vision-threatening infection. Further, many of thesee:
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ease which leaves them more susceptible to infection.
Recently, a number of severe infections have been associated
with pharmacy-compounded ophthalmic preparations, which
are normally not preserved, because of contamination during
compounding,3,4 but for commercially prepared topical oph-
thalmic preparations, contamination usually occurs as a result
of poor patient compliance.5–8 Prior to adequately preserved
ophthalmic drugs, several severe, blinding infections were
traced to in-use contamination of multidose preparations.9,10
For these reasons, manufactured topical ophthalmic prepara-
tions are required to be sterilely created and to be preserved
against secondary contamination. Unfortunately, the addi-
tives required for preservation may themselves be toxic to
the eye requiring the physician to have a thorough under-
standing of the potential risks of toxicity, therapeutic efficacy
and risk of infection for each individual patient in deciding on
appropriate medical management.Antimicrobial efficacy testing (AET)
All manufactured multidose ophthalmic products are
required to resist contamination both in the U.S., Japan
and the European Union. Their tests differ slightly, but signif-
icantly in some cases. Since it would be difficult to test pre-
servative efficacy against every possible contaminating
pathogen, each involves the testing of solutions against a
small number of bacteria and fungi chosen with the results
proxied as a general measure of contamination prevention.
The same general principle is applied to other ophthalmic
products, such as contact lens disinfection systems. These
tests are clearly not perfect and, combined with minimal
post-market surveillance, are not validated as reflective of
real world efficacy. Failures result from a number of factors
including an inadequate representation of poor patient com-
pliance and an inadequate reflection of potentially patho-
genic organisms. A recent example was the recent
outbreak of Fusarium keratitis as a result of the failure of
Renu with Moistureloc to adequately disinfect contact lenses
despite excellent antifungal activity on AET specific to con-
tact lens solutions.11–14
Current United States Pharmacopoeia (USP) Antimicrobial
Effectiveness Testing involves 3 stock bacteria (Pseudomonas
aeruginosa, Staphylococcus Aureus and Escherichia coli) and
2 fungi (Candida albicans and Aspergillus niger). Ophthalmic
compounds are Category 1 and the methodology is similar to
that specified in the Japan Pharmacopoeia. These organisms
are cultured and added to the solution to be tested with a
final concentration of between 1  105 and 1  106 colony
forming units (CFU). The solutions are then sampled at 7,
14 and 28 days with a requirement of a 1 log unit reduction
at 7 days, a 3 log unit reduction at 14 days and no increase
in CFUs from Day 14 to 28 for bacterial pathogens. For fungi,
the requirement is simply no increase in CFUs from the initial
inoculum at any of the three time points. European Pharma-
copoeia standards are significantly more stringent. Ophthal-
mic products for topical use are considered category EP-A
where 2 bacteria (P. aeruginosa and S. Aureus) and 2 fungi
(C. albicans and Aspergillus brasiliensis) are inoculated into
the solution to be tested. Samples for bacteria are taken at
6 and 24 h and then at 28 days with passing criteria of reduc-
tion in CFUs by 2 log units at 6 h, 3 log units at 24 h and nosubsequent increase at 28 days. Fungi are tested at 7 and
28 days with a required reduction in CFUs of 2 log units at
7 days without an increase from this point at 28 days.15Efficacy and toxicity of current ophthalmic
preservatives
The number of ophthalmic solution preservatives in cur-
rent use is relatively small and can be classified into two or
three categories (Table 1). Surfactants, or detergents,
directly damage the cell wall of microbes by disrupting their
lipid component causing cell lysis. Because of their non-spe-
cific nature, these agents are both generally more effective
with a broad spectrum of activity across different classes of
pathogens but are more toxic to human cells. Oxidizing pre-
servatives are small molecules that can pass the microbial cell
wall to enter the cell and disrupt internal enzymatic function.
These tend to be less toxic to human ocular surface cells, but
its efficacy against pathogens and pathogen classes outside
of those included in the testing regimen are either unknown
or unreported. Recently, an ionic buffer system was intro-
duced which acts similarly as an oxidizer while in solution.
Because these compounds are highly reactive, they will rap-
idly be consumed when in contact with the ocular surface.
The simplest alternative to preservation of multidose
preparations is sealed, unpreserved, single dose aliquots.
These not only eliminate the need for preservative additives,
but also the cycle of contamination, incubation and prolifera-
tion which would increase the concentration of microbes to
an infectious level. Unfortunately, the cost of production is
significantly higher resulting in higher costs to the patient.
Although they are labeled for single use, studies have dem-
onstrated that repeated use of a single dose applicator over
a 10 h period results in a relatively low rate (2.4%) of contam-
ination, dependent on the type of drug and patient compli-
ance.16,17 Another study suggested a relatively low rate of
contamination even if used for a longer period of time.16
The contamination risk of a particular compound is depen-
dent multiple factors including not only patient handling
and compliance, but also on the compound itself. Unless
there is gross contamination, growth and proliferation of
the pathogen after inoculation of the preparation is likely
required to reach an infectious threshold concentration.
Some microbes have demonstrated the ability to use the
base drug, such as corticosteroids, in these preparations as
a carbon source (food) to support this growth.18 There is evi-
dence that corticosteroids themselves further influence
microbial growth in both an inhibitory and supportive role
through hormonal action. Consequentially, corticosteroid
and corticosteroid combination medications have been
shown to have a much higher rate of contamination than
other medications.19Detergents
Benzalkonium chloride is a quaternary ammonium cationic
surfactant which has been the dominant ophthalmic preser-
vative over the past several decades. Found in over 70% of
topical ophthalmic drugs, it combines the advantage of
highly efficacious antimicrobial action with limited ocular
penetration and excellent solution stability. The compound
has been demonstrated to have a very broad spectrum of
Table 1. Common ophthalmic compounds and their primary preservative additive.*
Drug class Drug name Primary preservative Concentration
Ocular hypotensives
Miotics Echothiophate Chlorobutanol 0.55%
Pilocarpine BAK 0.01%
Pilocarpine gel BAK 0.008%
Carbachol BAK 0.005%
Beta blockers Timolol maleate (PFU) BAK 0.01%
Timolol XE Benzododecinium
bromide
0.012%
Cartelol BAK 0.005%
Betaxalol BAK 0.01%
Levabunolol BAK 0.005%
Metipranolol BAK 0.004%
Apraclonidine (PFU) BAK 0.01%
Brimonidine BAK 0.005%
Alphagan BAK 0.005%
Alphagan-P Purite 0.005%
Brinzolamide BAK 0.01%
Dorzolamide BAK 0.0075%
Prostaglandin analogs Latanoprost BAK 0.02%
Bimatoprost 0.01% BAK 0.02%
Bimatoprost 0.03% BAK 0.005%
Travoprost BAK 0.015%
Travoprost Z Sofzia Ionic buffer system
(Sofzia)
Tafluprost (PFU) N/A N/A
Rescula BAK 0.015%
Combination drugs Brimonidine/Timolol BAK 0.005%
Timolol/Dorzolamide BAK 0.0075%
Brinzolamide/Brimonidine BAK 0.003%
Anti-infectives
Antibacterials Gentamicin BAK 0.02%
Gentamicin ointment Methylparaben/
Propylparaben
Tobramycin BAK 0.02%
Sulfacetamide BAK 0.01%
Polysporin/trimethoprim sulfa BAK 0.004%
Gramicidin/Neosporin/polymyxin b (solution) Thimerosal 0.001%
Bacitracin/Neosporin/polymyxin b (ointment) PF None
Bacitracin/ Polymyxin b (ointment) PF N/A
Ciprofloxacin BAK 0.006%
Ofloxacin BAK 0.005%
Norfloxacin BAK 0.0025%
Levofloxacin 0.5% BAK 0.005%
Levofloxacin 1.5% PF N/A
Gatifloxacin BAK 0.005%
Moxifloxacin PF N/A
Besifloxacin BAK 0.01%
Azithromycin BAK 0.003%
Chloramphenicol Phenylmercuric nitrate 0.002%
Erythromycin (ointment) PF N/A
Oxytetracycline/polymyxin b
Antifungal Natamycin BAK 0.02%
Corticosteroid/ Antibiotic
Combinations
Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and
Hydrocortisone (ointment)
PF N/A
Loteprednol/tobramycin BAK 0.01%
Sulfacetamide 10%/Prednisolone acetate (drops) BAK 0.004%
Sulfacetamide 10%/ Prednisolone acetate (ointment) Phenylmercuric acetate 0.0008%
Tobramycin/Dexamethasone (ointment) Chlorobutanol 0.5%
Tobramycin/Dexamethasone (drops) BAK 0.01%
Sulfacetamide/Prednisolone phosphate Thimerosal 0.01%
Antivirals Vidarabine PF N/A
Idoxuridine BAK 0.01%
Trifluridine Thimerosal 0.001%
Ganciclovir BAK 0.0075%
Anti-Inflammatories/anti-infectives
NSAIDs Cromolyn Sodium BAK 0.01%
Diclofenac Sorbic Acid 0.2%
Ketorolac 0.4% BAK 0.006%
Ketorolac 0.5% BAK 0.01%
Nepafenac BAK 0.005%
Anti-allergics Ketotifen BAK 0.01%
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Table 1 (continued)
Drug class Drug name Primary preservative Concentration
Naphazoline BAK 0.01%
Olopatadine BAK 0.01%
Necrodomil BAK 0.01%
Epinastine BAK 0.01%
Lodoxamide BAK 0.01%
Alcaftadine BAK 0.005%
Corticosteroids Loteprednol BAK 0.007%
Fluorometholone BAK 0.005%
Prednisolone acetate BAK 0.01%
Prednisolone phosphate BAK 0.01%
Dexamethasone Phosphate (drops) BAK 0.02%
Rimexolone BAK 0.01%
Difluprednate Sorbic acid 0.1%
Artificial Tears
Bion Tears (PFU) PF N/A
Genteal family (PFU) Sodium Perborate
Hypotears BAK 0.01%
Systane lubricant eye gel Sodium perborate
Systane (ointment) PF N/A
Tears Naturale II Polyquaternium-1 0.001%
Tears Naturale Forte Polyquaternium-1 0.001%
Systane Ultra Polyquaternium-1 0.001%
Systane Balance Polyquaternium-1 0.001%
Refresh family (PFU) Purite
Soothe Hydration Sorbic Acid 0.1%
Soothe Long-lasting BAK 0.005%
Soothe Tired BAK 0.01%
Theratears Sodium perborate
Visine BAK
BAK - Benzalkonium chloride, PFU - Preservative -Free Unit Dose, PF- Preservative Free.
* Many preparations include other components which may have antimicrobial effect, e.g. EDTA, boric acid, etc.. . . which are proportionally less toxic.
Study of topical ophthalmic preservatives 185activity in vitro against all pathogen classes including acanth-
amoebae.20 Since its introduction, it has been known to
cause significant ocular surface toxicity where the drug is
preferentially absorbed, the conjunctiva and corneal epithe-
lium.21,22 Radioisotope studies indicate virtually no penetra-
tion into the aqueous humor, iris, ciliary body or vitreous
with minimal penetration into the corneal stroma with a sin-
gle drop on short term application.23–25 Although a single
study suggested that its resident time in tears is very short,26
this is probably due to its rapid uptake by the surface epithe-
lium. Several studies have demonstrated the significant ocu-
lar surface toxicity especially in compromised ocular
surfaces or with extended and/or frequent use.19,27–30 BAK
has been demonstrated in in vitro studies to induce apopto-
sis. Recently, however, further concerns have been raised
about the potential for intraocular penetration having been
found in animal studies in the area of the trabecular mesh-
work, choroid and even the optic nerve.31–33 This raises the
possibility of direct toxic effects on the nerve as well as
advancing trabecular meshwork changes which may lead to
further reduction in outflow facility. It should be noted that
this was observed in at 5 months of normal dosing at 0.01%
and primarily anterior segment penetration was seen at a
the excessive concentration of 0.2% once a day for 1 month.
Polyquaternium-1 is a quaternary ammonium compound
with a spectrum of activity against primarily bacteria with
some antifungal activity against yeasts presumed to act on
cell membranes.34 Although similar to BAK, it has limited
activity against other fungi and acanthamoeba. While
in vivo and in vitro studies demonstrate less toxicity in com-
parison to BAK, toxicity is still seen in the concentrations used
in ophthalmic compounds- primarily artificial tears (Table 1)
and contact lens solutions.35–38 Benzododecinium bromideis another quaternary ammonium compound which has a sim-
ilar mechanism of action.
Organomercurial compounds are primarily used in legacy
medications and consists of thimerosal as well as phenylmer-
curic acetate and nitrate (Table 1). Thimerosal is an organic
mercurial compound that was very commonly used in contact
lens disinfection systems. Reports of severe ocular surface
toxicity caused these solutions to be phased out.39 These
compounds bind to the cell wall, increasing permeability
and cell death.40–42 Sorbic acid has minimal primary antimi-
crobial activity, but may acidify the cell environment resulting
in inhibition of microbial growth.41
Chlorobutanol formed by the combination of chloroform
and acetone is sparingly used as an ophthalmic preservative
(Table 1), limited by its lability when exposed to heat or even
room temperature. Like benzalkonium chloride, it acts as a
detergent to non-specifically disrupt cell membranes and
has a broad spectrum of anti-microbial activity but is less
effective.41,43 Studies have shown that it is less toxic than
benzalkonium chloride both in vitro and in vivo, but still
remains more toxic than most oxidative preservatives at the
concentrations used for ophthalmic compounds.21,29Oxidative preservatives
Stabilized Oxychloro Complex (SOC) (Purite) is a combina-
tion of chlorine dioxide, chlorite and chlorate which causes
oxidation of intracellular lipids and glutathione, interrupting
vital enzymes for cell function and maintenance.41,44 It has
demonstrated antimicrobial activity against bacteria, viruses
and some fungi. Because of its propensity to generate free
radicals, it is an effective oxidizer and also breaks down
186 E.Y. Turapidly when exposed to the ocular surface. Although the
compound passes the USP AET, studies have suggested that
the slower microbial killing rates in artificial tear preparations
would not pass EP-A criteria for ophthalmic preservation.43
Sodium perborate (GenAqua) is another oxidative preser-
vative which is used as a bleaching agent in dentistry albeit at
higher concentrations. It acts by forming hydrogen peroxide,
a powerful oxidizing agent and antimicrobial, when com-
bined with water leading to a similar mechanism of action
as SOC.41,44 This also leads to its rapid degradation when
exposed to tears. It conforms to the USP AET test and hydro-
gen peroxide does have anti-acanthamoebal activity, but
data are limited beyond the required testing.45 Hydrogen
peroxide can cause significant ocular toxicity at higher levels,
but the concentration in the artificial tear products is reason-
ably well tolerated.46Alternative systems
SofZia is a unique preservative system that is composed of
boric acid, propylene glycol, sorbitol, and zinc chloride which
creates an ionic buffer system which has antibacterial and
antifungal activities. Like other oxidative preservatives, it
degrades quickly when exposed to the ocular toxicity. It is
very well tolerated in vivo and in vitro and significantly less
toxic than BAK.47,48 However, the antimicrobial action is slow
to a microbial challenge causing it to fail EP-A criteria. Inter-
estingly, a related preservation system which also passed
USP AET testing was introduced for a multidose form of Sys-
tane Free demonstrating adequate or superior antimicrobial
activity when compared to other artificial tears.45 After its
commercial introduction, however, several reports of mold
growth in Systane Free Liquid Gel led to its recall and elimi-
nation from the market in 2006. Although Travatan Z does
not contain the aminomethylpropanol component pointed
to by the manufacturer as the promoter of the contamination,
it does suggest when considered in the context of its failure
to meet EP-A criteria that it is not a comparatively robust pre-
servative system.Conclusion
Toxicity from topical compounds may be a result of either
the active drug, one of the other components in the prepara-
tion or both. The toxicity of benzalkonium chloride to the
ocular surface is well known and may result in both short term
and permanent alterations to the ocular surface including lim-
bal stem cell deficiency. Of equal concern are the potential
side effects in patients requiring BAK-containing compounds
under chronic therapy even at low doses. It is important to
understand, however, that BAK remains the gold standard
for preservative efficacy in ophthalmic solutions and, despite
this, ‘‘in-use’’ solution studies continue to show high levels of
contamination and can lead to severe ocular surface infec-
tions.7–10 Although controversial, there is some evidence that
the epithelial toxic effects may aid in penetration of certain
medications and that BAK may have therapeutic effects in
patients being treated for different forms of infectious kera-
titis where the short term use of a BAK-containing drug is
likely relatively safe.20,33
Unfortunately, the level of antimicrobial activity of all of
the current ophthalmic preservatives is, at this point in time,largely inversely proportional to its compatibility with the
ocular surface. Specifically, compounds that are highly effec-
tive antimicrobials are toxic to the ocular surface and those
which have less robust antimicrobial activity sufficient to pass
some AETs are relatively non-toxic. Given current knowl-
edge, for short term indications where the risk of contamina-
tion or secondary infection is high, choosing a preparation
with the best preservation efficacy is reasonable. These indi-
cations would include infectious keratitis, prophylaxis for epi-
thelial defects, surgical prophylaxis, etc. Patients with ocular
surface disease would likely demand the use of unpreserved,
unit dose medications for long or short term use. While a
patient with a healthy ocular surface which, on its own, would
confer some resistance to infection, a less efficacious but also
less toxic preservative would suffice. Further, the concentra-
tion of preservative may not be entirely indicative of a prep-
aration’s toxicity as other factors including frequency of
dosing and resident time on the ocular surface will affect
the amount of exposure. The ophthalmologist is then left to
individualize medication choices based on risk of infection
and contamination balancing the risks of both ocular surface
toxicity and the potential for other adverse effects.Financial disclosure
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